{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:16:22Z","timestamp":1787991382497,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006110","name":"Academy of Nutrition and Dietetics Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000199","name":"US Department of Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022967","name":"University of California Davis College of Agricultural and Environmental Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022967","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100292","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:50:55Z","timestamp":1782715855000},"page":"100292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1685-0360","authenticated-orcid":false,"given":"Demsina","family":"Babazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Therrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-1503","authenticated-orcid":false,"given":"Francene M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.obpill.2026.100292_bib1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP Trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.obpill.2026.100292_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.obpill.2026.100292_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.obpill.2026.100292_bib4","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.obpill.2026.100292_bib5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/dom.70436","article-title":"Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)","volume":"28","author":"Wilson","year":"2026","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2026.100292_bib6","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1111\/dom.70752","article-title":"Semaglutide and cardiovascular outcomes according to baseline aspirin use: analyses of the SOUL and SELECT trials","volume":"7","author":"Muller-Wieland","year":"2026","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.obpill.2026.100292_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2025.100491","article-title":"Examining the omission of dietary quality data in glucagon-like peptide 1 clinical trials: a scoping review","volume":"16","author":"Babazadeh","year":"2025","journal-title":"Adv Nutr"},{"key":"10.1016\/j.obpill.2026.100292_bib8","article-title":"Nutritional status with tirzepatide in obesity: a post hoc analysis of the SURMOUNT-1-4 randomized clinical trials","volume":"17","author":"Almandoz","year":"2026","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2026.100292_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2020.104711","article-title":"Food cravings: associations with dietary intake and metabolic health","volume":"152","author":"Taetzsch","year":"2020","journal-title":"Appetite"},{"issue":"10","key":"10.1016\/j.obpill.2026.100292_bib10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2026.100292_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107927","article-title":"Glucagon-like peptide-1 receptor agonists and muscle mass effects","volume":"220","author":"Ceasovschih","year":"2025","journal-title":"Pharmacol Res"},{"issue":"21","key":"10.1016\/j.obpill.2026.100292_bib12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1093\/eurheartj\/ehag201","article-title":"Fat, muscle, and anti-obesity medications in cardiovascular disease prevention","volume":"47","author":"Khan","year":"2026","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.obpill.2026.100292_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American college of lifestyle medicine, the American society for nutrition, the obesity medicine association, and the obesity society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.obpill.2026.100292_bib14","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2026.100292_bib15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.appet.2017.09.025","article-title":"Effects of 3-week total meal replacement vs. typical food-based diet on human brain functional magnetic resonance imaging food-cue reactivity and functional connectivity in people with obesity","volume":"120","author":"Kahathuduwa","year":"2018","journal-title":"Appetite"},{"issue":"9","key":"10.1016\/j.obpill.2026.100292_bib16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jand.2018.05.021","article-title":"Update of the healthy eating index: HEI-2015","volume":"118","author":"Krebs-Smith","year":"2018","journal-title":"J Acad Nutr Diet"},{"issue":"9","key":"10.1016\/j.obpill.2026.100292_bib17","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jand.2018.05.019","article-title":"Evaluation of the healthy eating Index-2015","volume":"118","author":"Reedy","year":"2018","journal-title":"J Acad Nutr Diet"},{"issue":"2","key":"10.1016\/j.obpill.2026.100292_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/oby.2002.17","article-title":"Development and validation of the food-craving inventory","volume":"10","author":"White","year":"2002","journal-title":"Obes Res"},{"issue":"8","key":"10.1016\/j.obpill.2026.100292_bib19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/aje\/kwm040","article-title":"Assessing the measurement properties of neighborhood scales: from psychometrics to ecometrics","volume":"165","author":"Mujahid","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.obpill.2026.100292_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/aje\/kwr445","article-title":"Measuring availability of healthy foods: agreement between directly measured and self-reported data","volume":"175","author":"Moore","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100292_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/pop.2020.0183","article-title":"Validation of a 2-Item food insecurity screen among adult general medicine outpatients","volume":"24","author":"Harrison","year":"2021","journal-title":"Popul Health Manag"},{"issue":"2","key":"10.1016\/j.obpill.2026.100292_bib22","article-title":"Development of the 7-Item binge-eating disorder screener (BEDS-7)","volume":"18","author":"Herman","year":"2016","journal-title":"Prim Care Companion CNS Disord"},{"issue":"2","key":"10.1016\/j.obpill.2026.100292_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0195-6663(93)90008-8","article-title":"The validity of appetite ratings","volume":"21","author":"de Graaf","year":"1993","journal-title":"Appetite"},{"issue":"10","key":"10.1016\/j.obpill.2026.100292_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM198603063141003","article-title":"Physical activity, all-cause mortality, and longevity of college alumni","volume":"314","author":"Paffenbarger","year":"1986","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.obpill.2026.100292_bib25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ejcn.2017.27","article-title":"Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices","volume":"71","author":"Bosy-Westphal","year":"2017","journal-title":"Eur J Clin Nutr"},{"issue":"19","key":"10.1016\/j.obpill.2026.100292_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph181910094","article-title":"Feasibility of using bioelectrical impedance analysis for assessing youth weight and health status: preliminary findings","volume":"18","author":"Howe","year":"2021","journal-title":"Int J Environ Res Publ Health"},{"issue":"11","key":"10.1016\/j.obpill.2026.100292_bib27","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae164","article-title":"Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments","volume":"8","author":"Tinsley","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.obpill.2026.100292_bib28","series-title":"Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids","year":"2005"},{"key":"10.1016\/j.obpill.2026.100292_bib29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clnesp.2024.06.030","article-title":"Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight\/obesity: a systematic review and meta-analysis","volume":"63","author":"Kokura","year":"2024","journal-title":"Clin Nutr ESPEN"},{"issue":"10516","key":"10.1016\/j.obpill.2026.100292_bib30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.obpill.2026.100292_bib31","first-page":"521","article-title":"The impact and utility of very low-calorie diets: the role of exercise and protein in preserving skeletal muscle mass","volume":"26","author":"Janssen","year":"2023","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.obpill.2026.100292_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2025.1566498","article-title":"Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study","volume":"12","author":"Johnson","year":"2025","journal-title":"Front Nutr"},{"issue":"5","key":"10.1016\/j.obpill.2026.100292_bib33","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.obpill.2026.100292_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00592-025-02611-2","article-title":"Muscle loss and GLP-1R agonists use","volume":"63","author":"Rossi","year":"2026","journal-title":"Acta Diabetol"},{"issue":"11","key":"10.1016\/j.obpill.2026.100292_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdnut.2025.107587","article-title":"GLP-1 receptor agonists - good for body weight, bad for micronutrient status?","volume":"9","author":"Kerlikowsky","year":"2025","journal-title":"Curr Dev Nutr"},{"issue":"19","key":"10.1016\/j.obpill.2026.100292_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/nu15194283","article-title":"Diet quality, cardiometabolic risk and diabetes","volume":"15","author":"Della Pepa","year":"2023","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.obpill.2026.100292_bib37","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/s41366-025-01902-6","article-title":"Effect of weight loss through dietary interventions on cardiometabolic health in older adults","volume":"49","author":"Dhana","year":"2025","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"10.1016\/j.obpill.2026.100292_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/nu11020338","article-title":"DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses","volume":"11","author":"Chiavaroli","year":"2019","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.obpill.2026.100292_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000047994","article-title":"GLP-1 receptor agonists for weight loss: a systematic review and meta-analysis of randomized controlled trials","volume":"105","author":"Ahmad","year":"2026","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.obpill.2026.100292_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjnph-2025-001206","article-title":"GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction","volume":"8","author":"Mocciaro","year":"2025","journal-title":"BMJ Nutr Prev Health"},{"issue":"2","key":"10.1016\/j.obpill.2026.100292_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15020541","article-title":"Pharmacologic treatments for the preservation of lean body mass during weight loss","volume":"15","author":"Arora","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.obpill.2026.100292_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.obpill.2026.100292_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/nu18010131","article-title":"Nutrition and physical activity in optimizing weight loss and lean mass preservation in the incretin-based medications era: a narrative review","volume":"18","author":"Barana","year":"2025","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.obpill.2026.100292_bib44","article-title":"Effects of tirzepatide on skeletal muscle mass in adults: a systematic review","volume":"17","author":"Hidalgo Ramos","year":"2025","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.obpill.2026.100292_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/obr.70049","article-title":"GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: a rapid review of changes in eating behaviors and eating disorder risk","volume":"27","author":"Jebeile","year":"2026","journal-title":"Obes Rev"},{"issue":"11","key":"10.1016\/j.obpill.2026.100292_bib46","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1111\/dom.70063","article-title":"Impact of tirzepatide treatment on participant-reported food craving and food preference: secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction","volume":"27","author":"Kennedy","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.obpill.2026.100292_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/cob.70070","article-title":"Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review","volume":"16","author":"Urbina","year":"2026","journal-title":"Clin Obes"},{"issue":"35","key":"10.1016\/j.obpill.2026.100292_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039542","article-title":"Comparative analysis of basal metabolic rate measurement methods in overweight and obese individuals: a retrospective study","volume":"103","author":"Karagun","year":"2024","journal-title":"Medicine (Baltim)"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:29:35Z","timestamp":1787988575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"alternative-id":["S2667368126000483"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100292","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100292"}}